Amarin Corp Plc (AMRN)

[HinduKush]

STS
This was a study of 68 patients, with 31 and 37 patients in the IPE and placebo arms. That it showed such profound plaque effects in such a relatively small sample is testament to the profound nature of the clinical effect (think how many patients were needed to prove CV death and CV event reductions in R-IT). Actually the calcified plaque effect was borderline to disproving the null hypothesis and a whisker away from proving (by P<0.05 criteria) that it does reduce calcified plaque by conventional measures of statistical significance. Meaning to say had we haundred patients in each arm an extneded to 2 years the study we would have easily shown it (IHMO). Also realize that calcified plaque takes time to develop and in an early stage of atherosclerosis progresson the non-calcified prevalence will be greater-this is borne out in teh prevalence of the different types of plaque illustrated in the EVAPORATE results...see below: HK